XNK03 / XNK Therap - LARVOL DELTA

XNK Therapeutics to present two posters at the NK2023 conference in Oslo in September (PRNewswire) - "XNK Therapeutics AB today announced that two posters, regarding bladder cancer and acute myeloid leukemia (AML) respectively, will be presented at the 20th Meeting of the Society for Natural Immunity (NK2023) in Oslo, Norway, in September...The data have been generated in collaboration with XNK's external partners, Anders Ullén and Fernanda Costa Svedman at the Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden, for the bladder cancer abstract, and Abhishek Maiti and Naval Daver at The University of Texas MD Anderson Cancer Center in Houston, Texas, USA, for the AML abstract."

Clinical data • Acute Myelogenous Leukemia • Bladder Cancer • Genito-urinary Cancer • Hematological Malignancies • Leukemia • Oncology • Solid Tumor • Urothelial Cancer

XNK Therapeutics to present two abstracts at the Society for Immunotherapy of Cancer's meeting in San Diego in November (PRNewswire) - "XNK Therapeutics...announced that the abstracts Harnessing the potential of autologous NK cells for immunotherapy of patients with advanced bladder cancer and Feeder-Free Expansion of Autologous Cytotoxic NK Cells for Acute Myeloid Leukemia Treatment will be presented at the 38th Meeting of the Society for Immunotherapy of Cancer (SITC) in San Diego in November....The data have been generated in collaboration with XNK's external partners, Anders Ullén and Fernanda Costa Svedman at the Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden, for the bladder cancer abstract, and Abhishek Maiti and Naval Daver at The University of Texas MD Anderson Cancer Center in Houston, Texas, USA, for the AML abstract."

Preclinical • Acute Myelogenous Leukemia • Bladder Cancer • Genito-urinary Cancer • Hematological Malignancies • Leukemia • Oncology • Solid Tumor

First patient cells collected in XNK’s preclinical bladder cancer study (PRNewswire) - "XNK Therapeutics AB...announced that the first patient has donated cells in the recently initiated preclinical evaluation of the autologous NK cell product XNK03 in locally advanced or metastatic urothelial cancer. The study is performed in collaboration with Anders Ullén's research group at the Karolinska University Hospital, Stockholm, Sweden....Between 10-15 patients with advanced urothelial cancer will be enrolled in the study and will donate cells before and after chemotherapy treatment."

Preclinical • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer